Bilateral Hand Transplant in India and UAE | Complete Patient Guide

ELIGIBILITY CRITERIA

• Bilateral upper-limb amputation at or proximal to the radiocarpal (wrist) joint, with documented failure or inadequacy of prosthetic rehabilitation

• Age range: 18–60 years (pediatric cases evaluated individually; elderly patients excluded due to immunosuppression risk-benefit ratio)

• Adequate residual forearm musculature to enable motor re-innervation; ideally amputation level distal to the elbow (trans-radial or transcarpal)

• Documented stable psychiatric status: absence of active psychosis, substance use disorder, or personality disorders that would compromise medication adherence

• Strong social support network and confirmed commitment to a 12–24 month intensive hand therapy program

• Non-smoker for ≥6 months prior to listing (nicotine causes microvascular vasospasm, significantly increasing anastomotic thrombosis risk)

• No active systemic infection, active malignancy, or uncontrolled autoimmune disease

• Negative cross-match (complement-dependent cytotoxicity and flow cytometry) with prospective donor

REQUIRED PRE-OPERATIVE DIAGNOSTICS

• HLA typing (high-resolution Class I and Class II), ABO/Rh blood grouping, and Panel Reactive Antibody (PRA) screening

• Doppler ultrasound and CT angiography of residual stumps to map proximal vessel diameter and caliber

• MRI of residual forearm musculature (to assess motor unit viability for re-innervation)

• Nerve conduction studies (NCS) of proximal median, ulnar, and radial nerves

• Comprehensive metabolic panel, full lipid profile, HbA1c, eGFR, LFTs (baseline organ function prior to calcineurin inhibitor initiation)

• Cardiac evaluation: 12-lead ECG, echocardiography (ECHO), and cardiopulmonary exercise testing (CPET) for surgical fitness

• Chest CT and whole-body PET-CT to exclude occult malignancy

• Infectious disease screening: HIV, HBsAg, anti-HCV, CMV IgG/IgM, EBV, TB (IGRA/QuantiFERON-TB Gold), syphilis

• Formal neuropsychological evaluation and structured psychiatric clearance

• Bone densitometry (DEXA scan) as baseline before long-term corticosteroid therapy

CONTRAINDICATIONS

• Active or recent malignancy (within 5 years, excluding non-melanoma skin cancer)

• Severe systemic illness: decompensated heart failure, advanced CKD (eGFR <30 mL/min), uncontrolled diabetes mellitus

• High-titer pre-formed donor-specific antibodies (DSA) on flow cytometry cross-match

• Active or chronic infections incompatible with immunosuppression (e.g., untreated TB, HIV with CD4 <200 cells/µL)

• Bilateral amputation proximal to the elbow (transhumeral level) — limited motor substrate for re-innervation reduces functional outcomes significantly

• Demonstrated inability or refusal to comply with immunosuppression or therapy protocols

• Body mass index (BMI) >35 (significantly increases wound healing complications and anesthetic risk for a >12-hour procedure)

PHASE 1 — DONOR PROCUREMENT AND ALLOGRAFT PREPARATION

The procedure is initiated only upon confirmation of a brain-dead, hemodynamically stable donor with compatible HLA/ABO profile and negative cross-match. Ischemia time is the critical variable: warm ischemia must not exceed 6 hours, and cold ischemic time (with perfusion using University of Wisconsin or HTK solution) should ideally remain below 4–6 hours to maximize microvascular viability. The procurement team harvests both donor hands en bloc with the distal forearm, preserving maximum vessel, nerve, and tendon length. Simultaneous recipient stump preparation — debridement, vessel isolation, nerve identification, and osteotomy — is performed by a parallel team in an adjacent operating room to minimize total ischemia time.

PHASE 2 — SKELETAL FIXATION

Rigid skeletal fixation is the foundation of the reconstruction and is performed first to restore anatomical length and rotational alignment. Techniques include:

• Plate-and-screw osteosynthesis using low-profile titanium locking plates applied to the radius and ulna (or metacarpals for transcarpal-level transplants)

• Intramedullary fixation for distal forearm amputations

• Kirschner wire (K-wire) fixation for carpal-level anastomoses

In select centers, computer-assisted surgical planning (CASP) and patient-specific implant (PSI) technology are used to pre-operatively model osteotomy cuts and plate positioning, reducing intraoperative time significantly.

PHASE 3 — TENDON REPAIR

Flexor and extensor tendons are repaired using the modified Kessler or Adelaide technique with 4-0 braided polyester sutures, achieving a minimum four-strand core purchase to withstand early active motion protocols during therapy.

PHASE 4 — VASCULAR ANASTOMOSIS (MICROSURGERY)

This is the most technically demanding phase. Using an operating microscope at 6–25× magnification:

• Arterial anastomoses: radial and ulnar arteries are anastomosed end-to-end using interrupted 9-0 or 10-0 nylon sutures

• Venous anastomoses: a minimum of two venous anastomoses per hand (cephalic and basilic vein tributaries) are performed to ensure adequate outflow and prevent venous congestion — the most common cause of early graft loss

• Intraoperative perfusion is assessed using Laser Doppler flowmetry, near-infrared spectroscopy (NIRS) tissue oximetry, and fluorescence angiography (Spy Elite/SPY-PHI system) to confirm anastomotic patency before wound closure

PHASE 5 — NERVE COAPTATION

Median, ulnar, and radial nerves (and their sensory branches) are repaired under microscope using epineural sutures (10-0 nylon) or, where gaps exist, bridged with processed nerve allografts (Avance® Nerve Graft, AxoGen) or autologous sural nerve grafts. Sensory re-innervation typically precedes motor re-innervation by 3–6 months due to differential axonal regeneration rates.

PHASE 6 — SKIN CLOSURE AND FLAP MANAGEMENT

Skin closure is performed in layers. Color mismatch between donor and recipient skin is inevitable but typically acceptable. Dermal-epidermal interface is the primary antigenic target of rejection; sentinel skin biopsies are performed at regular intervals post-transplant to grade rejection using the Banff 2007 Classification for skin-containing VCA (Grade 0–IV).

IMMUNOSUPPRESSION PROTOCOL

Induction: Anti-thymocyte globulin (ATG, rabbit-derived, Thymoglobulin®) or Basiliximab (IL-2 receptor antagonist) administered perioperatively

Maintenance (triple therapy):

• Tacrolimus (target trough levels: 10–15 ng/mL in year 1; 5–10 ng/mL thereafter)

• Mycophenolate mofetil (MMF): 1.0–1.5 g twice daily

• Prednisolone: tapered from 1 mg/kg/day to ≤5 mg/day by 6 months

Emergent rejection episodes (Banff Grade III–IV) are treated with pulse intravenous methylprednisolone ± topical tacrolimus ointment for skin involvement

Prophylaxis: Valganciclovir (CMV prophylaxis), trimethoprim-sulfamethoxazole (PCP prophylaxis), fluconazole (antifungal), and low-molecular-weight heparin (LMWH) for early anticoagulation

ADVANCED & EMERGING APPROACHES

• Targeted tolerance induction protocols: Some advanced centers (e.g., University of Pittsburgh model) are investigating combined bone marrow infusion from the same donor (split-chimerism induction) to reduce long-term immunosuppression burden — currently experimental

• Robotic-assisted microsurgery: The Symani® Surgical System (Medical Microinstruments) enables tremor-filtered, motion-scaled robotic microsuturing, reducing anastomotic error rates in select high-volume centers

• Normothermic machine perfusion (NMP) of the donor hand: emerging technique to extend safe ischemia time and assess graft viability ex vivo before implantation

STAGE 1 — REMOTE EVALUATION & LISTING (4–8 weeks, conducted from home country)

• GAF Healthcare coordinates submission of complete medical records, imaging (MRI/CT angiography, nerve conduction studies), and psychiatric evaluation reports to the chosen transplant center

• Virtual multidisciplinary team (MDT) consultation with transplant surgeon, immunologist, hand therapist, and psychiatrist

• HLA typing blood samples can be drawn locally and shipped (dry ice, stabilized) to the receiving center's HLA laboratory

• Formal listing on the hospital's VCA waiting list upon MDT approval; waiting time is variable (months to years depending on donor availability)

STAGE 2 — DONOR ALERT & RAPID MOBILIZATION (24–72 hours)

• Upon donor identification and cross-match confirmation, patient receives emergency alert via GAF Healthcare's 24/7 coordination desk

• GAF Healthcare facilitates emergency medical visa processing (India: Emergency e-Medical Visa, typically expedited within 24–48 hours; UAE: visa-on-arrival or pre-approved medical visa)

• Emergency commercial or air ambulance transport arranged within hours

• Patient admitted to transplant center; urgent pre-operative workup completed (repeat cross-match, anesthesia review, consent)

STAGE 3 — SURGICAL PROCEDURE (Day 0; Duration: 12–18 hours)

• General endotracheal anesthesia with total intravenous anesthesia (TIVA) protocol to minimize vasoconstriction

• Simultaneous two-team approach: procurement team and recipient preparation team

• Sequential completion: osteosynthesis → tendon repair → arterial anastomosis → venous anastomosis → nerve coaptation → skin closure

• Transfer to Surgical ICU (SICU) with continuous Doppler monitoring probes secured over anastomotic sites

STAGE 4 — ICU MONITORING (Days 1–5)

• Hourly clinical assessment: capillary refill, skin temperature, Doppler signal, color, turgor

• NIRS tissue oximetry monitoring continuously for 48–72 hours

• Strict hand elevation above cardiac level to reduce edema

• Anticoagulation: IV heparin infusion transitioning to aspirin + dipyridamole by Day 3

• Immunosuppression induction completed; tacrolimus levels measured daily

• First dressing change and skin inspection at 48 hours

STAGE 5 — STEP-DOWN WARD (Days 6–21)

• Transition from ICU once vascular stability confirmed

• First sentinel skin biopsy at Day 7 (baseline rejection grading)

• Splinting protocol initiated: static volar resting splints maintaining wrist in neutral position

• Edema management: elevation, compression garments once wounds mature

• Oral immunosuppression regime finalized; nephrotoxicity and glucose monitoring intensified

• Infectious disease surveillance: CMV PCR weekly, wound swabs

• Patient education: self-monitoring for rejection signs (erythema, vesicles, induration over donor skin)

STAGE 6 — INTENSIVE INPATIENT HAND THERAPY (Weeks 3–8, typically at the same or affiliated rehabilitation center)

• Weeks 3–4: Passive range-of-motion (PROM) exercises to all finger and wrist joints; desensitization of palmar skin; mirror therapy for cortical remapping

• Weeks 5–6: Active-assisted ROM (AAROM) initiated as tendon healing confirmed by ultrasound; grip strengthening using theraputty

• Weeks 7–8: Functional task training — object manipulation, pinch grip, bimanual coordination tasks; sensory re-education with graded textural discrimination

• Milestone: Protective sensation (sharp/dull discrimination) typically returns by weeks 8–16 in the hand dorsum; palmar sensation follows over months

STAGE 7 — FIT-TO-FLY CLEARANCE (Weeks 12–16)

• Criteria for international travel clearance: stable tacrolimus trough levels within therapeutic range for ≥4 consecutive weeks; no acute rejection episode in preceding 6 weeks; wound fully epithelialized; absence of active infection; independent oral medication management

• GAF Healthcare provides a comprehensive medical discharge summary, immunosuppression prescription (bridging supply for 90 days), and a hand therapy home program

• Arrangements made for ongoing tacrolimus level monitoring at a laboratory in the patient's home country, with results transmitted digitally to the treating team

• Follow-up teleconsultations scheduled at weeks 1, 4, 8, 12, and 24 post-departure

STAGE 8 — LONG-TERM RECOVERY (Months 6–24, home country with remote monitoring)

• Motor re-innervation: intrinsic muscle function (lumbricales, interossei) returns approximately 12–18 months post-transplant as regenerating axons traverse from the proximal nerve repair site to terminal motor end-plates

• Milestone: Two-point discrimination (2PD) ≤10 mm (functional sensory recovery) is achieved in approximately 70% of patients by 24 months

• Milestone: Independent ADLs (feeding, grooming, writing) typically restored by 12–18 months

• Annual protocol skin biopsy and screening for calcineurin inhibitor-related nephrotoxicity (annual eGFR, urine albumin), post-transplant lymphoproliferative disorder (PTLD), and skin malignancy (annual dermatologic review)